Relationship between Vancomycin-Resistant Staphylococcus aureus, Vancomycin-Intermediate S. aureus, High Vancomycin MIC, and Outcome in Serious S. aureus Infections
Author(s) -
Natasha E. Holmes,
Paul D. R. Johnson,
Benjamin P. Howden
Publication year - 2012
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.00775-12
Subject(s) - staphylococcus aureus , vancomycin , microbiology and biotechnology , staphylococcal infections , methicillin resistant staphylococcus aureus , micrococcaceae , antibiotics , medicine , biology , antibacterial agent , bacteria , genetics
Vancomycin has been used successfully for over 50 years for the treatment ofStaphylococcus aureus infections, particularly those involving methicillin-resistantS. aureus . It has proven remarkably reliable, but its efficacy is now being questioned with the emergence of strains ofS. aureus that display heteroresistance, intermediate resistance, and, occasionally, complete vancomycin resistance. More recently, an association has been established between poor outcome and infections with strains ofS. aureus with an elevated vancomycin MIC within the susceptible range. This minireview summarizes the definitions, mechanisms, clinical impact, and laboratory identification of reduced vancomycin susceptibility inS. aureus and discusses practical issues for the diagnostic laboratory in testing and interpreting vancomycin susceptibility forS. aureus infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom